Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash from Operations (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Cash from Operations for 15 consecutive years, with 3675000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 26.51% to 3675000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 595000.0, a 188.41% decrease, with the full-year FY2025 number at 1937000.0, down 39.55% from a year prior.
  • Cash from Operations was 3675000.0 for Q4 2025 at Aytu Biopharma, up from 618000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 9371000.0 in Q2 2023 to a low of 9115000.0 in Q1 2022.
  • A 5-year average of 2129526.32 and a median of 1190000.0 in 2024 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: surged 2251.85% in 2024, then tumbled 2441.34% in 2025.
  • Aytu Biopharma's Cash from Operations stood at 8822000.0 in 2021, then soared by 71.8% to 2488000.0 in 2022, then surged by 94.57% to 135000.0 in 2023, then soared by 2251.85% to 2905000.0 in 2024, then increased by 26.51% to 3675000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Cash from Operations are 3675000.0 (Q4 2025), 618000.0 (Q3 2025), and 2803000.0 (Q2 2025).